Active and passive immunization for cancer

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 2123-2129

  Baxter, David ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b STEPPING HILL HOSPITAL   (United Kingdom)

Author keywords

Active and passive immunization; Therapeutic cancer vaccines

Indexed keywords

ANTIGEN; BCG VACCINE; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEPATITIS B VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY CD28; OPSONIN; TRASTUZUMAB; WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CELLULAR IMMUNITY; CIRCULATING TUMOR CELL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIPHTHERIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FEVER; HELPER CELL; HEPATITIS B; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; INFECTION; LIVER CANCER; LUNG CANCER; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MILIARY TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMOCOCCAL INFECTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; REPRODUCIBILITY; REVIEW; STOMACH CANCER; T LYMPHOCYTE; UNITED KINGDOM; UTERINE CERVIX CANCER; NEOPLASMS; PROCEDURES; VACCINATION;

HUMANS; IMMUNIZATION, PASSIVE; NEOPLASMS; VACCINATION;

EID: 84908432557     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29604     Document Type: Review

References (25)

1. Ahmad I, Longenecker M, Samuel J, Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 1993; 53:1484-8; PMID:8453612
2. Bazin H. A brief history of the prevention of infectious diseases by immunisations. Comp Immunol Microbiol Infect Dis 2003; 26:293-308; PMID:12818618; http://dx.doi.org/10.1016/S0147-9571(03)00016-X
3. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170:964-9; PMID:12913751; http://dx.doi.org/10.1097/01.ju.0000073852.24341.4a
4. Bosch FX. Human Papillomavirus Vaccination for the Prevention of Cervical and Other Related Cancers. Epidemiologic Studies in Cancer Prevention and Screening. Statistics for Biology and Health 2013; 79:45-64; http://dx.doi.org/10.1007/978-1-4614-5586-8-4
5. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23-34; PMID:21048000; http://dx.doi.org/10.1128/CVI.00286-10
6. Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009; 181:85-94; PMID:19213561; http://dx.doi.org/10.1007/978-3-540-69297-3-10
7. Coley WB. II. Contribution to the Knowledge of Sarcoma. Ann Surg 1891; 14:199-220; PMID:17859590; http://dx.doi.org/10.1097/00000658-189112000-00015
8. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991; 3-11; PMID:1984929
9. Dalgleish AG. Cancer vaccines. Br J Cancer 2000; 82:1619-24; PMID:10817493
10. Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs 2005; 19:247-60; PMID:16128607; http://dx.doi.org/10.2165/00063030-200519040-00004
11. Fehleisen F. (1883). "Die Aetiologie des Erysipels." Accessed at: https://archive.org/details/dieaetiologiede00fehlgoog.
12. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 2012; 5:70; PMID:23140144; http://dx.doi.org/10.1186/1756-8722-5-70
13. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 2011; 3:475-85; PMID:21463188; http://dx.doi.org/10.2217/imt.11.15
14. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
15. McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S; MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013; 24:2694-8; PMID:23942774; http://dx.doi.org/10.1093/annonc/mdt291
16. Parrish HJ. Victory with Vaccines: the story of immunization, by H. J. Parish, M.D., F.R.C.P.E., D.P.H., HON.F.R.S.H. 245 pp. E. & S. LIVINGSTONE LTD. Edinburgh and London, 1968. 1 10s. 0d.
17. Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 2009; 34:25-32; PMID:19082474
18. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 2013; 108:1560-5; PMID:23511566; http://dx.doi.org/10.1038/bjc.2013.117
19. Rettig WJ, Old LJ. Immunogenetics of human cell surface differentiation. Annu Rev Immunol 1989; 7:481-511; PMID:2653374; http://dx.doi.org/10.1146/annurev.iy.07.040189.002405
20. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
21. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
22. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850-61; PMID:12415255; http://dx.doi.org/10.1038/nrc928
23. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; http://dx.doi.org/10.1016/S1470-2045(12)70007-4
24. World Health Organization. The top ten causes of death (2002). Fact sheet No 310 / February 2007. Accessed at http://www.who.int/mediacentre/factsheets/fs310.pdf.
25. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073